Company: Chelsea Therapeutics [1]
Starting stock price: $3.82
Ending stock price: $7.85
Percent Change: 92.41%
Details: Chelsea Therapeutics is developing therapies for a number of inflammatory conditions. In 2007 the company won orphan status for Droxidopa, which treats low blood pressure stemming from Parkinson's or from multiple-system atrophy. The drug already has orphan status in the U.S. and is in Phase III trials. Chelsea also has the drug candidate CH-1504 in Phase II trials for rheumatoid arthritis, psoriasis and inflammatory bowel disease.
More News:
Chelsea wins European orphan status. Report [2]
FDA grants Droxidopa orphan drug status. Report [3]
Links:
[1] http://www.chelseatherapeutics.com/
[2] http://www.fiercebiotech.com/story/chelsea-wins-european-orphan-status/2007-08-15
[3] http://www.fiercebiotech.com/node/5314
[4] http://www.fiercepharma.com/special-reports/nexmed-best-pharma-stocks-2007
[5] http://www.fiercepharma.com/special-reports/best-pharma-stocks-2007
[6] http://www.fiercepharma.com/special-reports/obagi-medical-best-pharma-stocks-2007